menu
    • menu
    [{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Ion Channel Innovations","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SWITZERLAND","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Hmaxi-K","moa":"Maxi-K channel","graph1":"Urology","graph2":"Phase I","graph3":"Urovant Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Urovant Sciences \/ Ion Channel Innovations","highestDevelopmentStatusID":"6","companyTruncated":"Urovant Sciences \/ Ion Channel Innovations"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Dasman Diabetes Institute | Ion Channel Innovations","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Hmaxi-K","moa":"Maxi-K channel","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Urovant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Urovant Sciences \/ Dasman Diabetes Institute | Ion Channel Innovations","highestDevelopmentStatusID":"8","companyTruncated":"Urovant Sciences \/ Dasman Diabetes Institute | Ion Channel Innovations"}]

    Find Clinical Drug Pipeline Developments & Deals for Hmaxi-K

    Menu

    Hmaxi-K

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Urovant Sciences

                            Switzerland arrow
                            OTS 2025
                            Not Confirmed

                            Urovant Sciences

                            Switzerland arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hmaxi-K

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Dasman Diabetes Institute | Ion Channel Innovations

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 2A Clinical Trial Evaluating the Potential Activity and Safety of hMaxi-K Gene for ED

                            Details : Hmaxi-K is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Erectile Dysfunction.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            March 21, 2016

                            Lead Product(s) : Hmaxi-K

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Dasman Diabetes Institute | Ion Channel Innovations

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Urovant Sciences

                            Switzerland arrow
                            OTS 2025
                            Not Confirmed

                            Urovant Sciences

                            Switzerland arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hmaxi-K

                            Therapeutic Area : Urology

                            Study Phase : Phase I

                            Sponsor : Ion Channel Innovations

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 1 Study With OAB Assessing the Safety and Activity of hMaxi-K Gene Transfer

                            Details : Hmaxi-K is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Urinary Bladder, Overactive.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            June 05, 2013

                            Lead Product(s) : Hmaxi-K

                            Therapeutic Area : Urology

                            Highest Development Status : Phase I

                            Sponsor : Ion Channel Innovations

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth